Biotechnology

Kailera Therapeutics

Hengrui Medicine's HRS-7535 Phase III Trial Shows Positive Results, Plans to Submit NDA for Diabetes Drug

TD Cowen Analyst Werber Reaffirms Buy Rating on Kailera Therapeutics

TD Cowen initiates coverage of Kailera Therapeutics with a buy rating; sets target price at $57

Bain Capital Affiliate Buys Shares in Kailera Therapeutics and Plans to Collaborate

RTW Investments Increased Its Stake in Kailera Therapeutics

Bain Capital Increases Stake in Kailera Therapeutics to 10%

Andrew T. Kaplan Acquired Shares in Kailera Therapeutics

Kailera Therapeutics amends its charter to align with corporate governance provisions

Kailera Therapeutics, Inc. released FY2024 earnings on March 27 (EST) with actual revenue of USD 0 and EPS of USD 0

Kailera Therapeutics, Inc. released FY2025 Annual Earnings on March 27, 2026 (EST) with actual revenue of USD 0 and EPS of USD -7.82 K

DevvStream

Hub Cyber Security

Sunlands Tech

PRF Tech

Mynd.ai

Replimune

Tortoise Energy Infrastructure Corporation

Olenox Industries

Astrotech

GraniteShares 2x Long DELL Daily ETF

KLRA

Jefferies analyst Roger Song has maintained a Buy rating for Kailera Therapeutics, Inc. (KLRA) with a price target of $48.00. The analyst consensus suggests a Strong Buy rating for the company, with an average price target of $39.00. Song has a 40.86% success rate on his stock recommendations.

Tip Ranks

Jefferies Financial

United Therap

Oruka Therapeutics

Fate Therap

Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)

TD Cowen analyst Yaron Werber has reaffirmed a Buy rating on Kailera Therapeutics, Inc. (KLRA), with shares closing at USD21.57. The analyst consensus suggests a Strong Buy rating with an average price target of $39.00, indicating an 80.81% upside. Werber has a 24.3% average return and a 58.70% success rate on his recommendations.

Toronto Dominion Bank

Ionis Pharma

Argenx

Amgen

TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)

Earnings Watch

Kailera Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Kailera Therapeutics reported its Q1 2026 financial results, highlighting significant progress in its obesity pipeline, including the initiation of five late-stage global clinical trials. The company announced positive topline data from trials for ribupatide and other compounds, with cash on hand expected to fund operations into mid-2028. CEO Ron Renaud emphasized the momentum in advancing clinical programs and the potential of their ribupatide franchise in obesity management.

StockTitan

Hengrui Pharma

HENGRUI PHARMA

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | KLRA Stock News

William Blair has initiated coverage on Kailera Therapeutics (NASDAQ:KLRA) with an Outperform rating, highlighting its competitive edge in the weight-loss drug market. The company raised over $600 million in its IPO and is advancing a diverse pipeline, including its lead candidate ribupatide, a Phase 3 GLP-1/GIP dual agonist. Analysts believe Kailera's broad pipeline could address various patient needs, despite intense competition in the obesity market. The obesity treatment market is projected to exceed $100 billion by the 2030s, offering significant growth potential for new entrants like Kailera.

benzinga_article

Eli Lilly

First Trust NYSE Arca Biotech Index Fd

VG Health

Defiance Daily Target 2X Long LLY ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Direxion Daily LLY Bull 2X Shares

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Evercore

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst

BCPE Perseus Investor, LP has acquired a 20.3% stake in Kailera Therapeutics, Inc., which includes pre-IPO preferred shares and additional shares purchased on April 20, 2026. This investment grants Bain Capital’s affiliate significant influence, as it plans to actively collaborate with the company's management and board on various initiatives. Andrew Kaplan from Bain Capital already serves on the board, facilitating direct engagement. The investor may adjust its holdings over time, reflecting its commitment to ongoing performance and strategy reviews.

TradingView

BCPE Perseus Investor Takes Activist Stake at Kailera Therapeutics with 20.3% Stake

Kailera Therapeutics, Inc. (traded on Nasdaq under the symbol KLRA) disclosed today the pricing details of its initial public offering.

Unusual Whales

Kailera Therapeutics Announces Pricing of Initial Public Offering

Kailera Therapeutics(KLRA.US)